about
Factors determining patient-prosthesis mismatch after aortic valve replacement--a prospective cohort studyOutcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular PerformancePrognostic Impact of Tricuspid Regurgitation in Patients Undergoing Aortic Valve Surgery for Aortic Stenosis.Pulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fractionPresence of ´isolated´ tricuspid regurgitation should prompt the suspicion of heart failure with preserved ejection fractionEvaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial.Fluid status and outcome in patients with heart failure and preserved ejection fraction.Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction.Diameter of the Pulmonary Artery in Relation to the Ascending Aorta: Association with Cardiovascular Outcome.Interstitial Fibrosis, Functional Status, and Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From a Prospective Cardiac Magnetic Resonance Imaging Study.Modes of death in patients with heart failure and preserved ejection fraction.The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics.T1 Mapping by CMR Imaging: From Histological Validation to Clinical Implication.Clinical Neuropathology image 3-2017: CNS involvement in systemic amyloidosis restricted to the choroid plexus.Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size.Extracellular volume quantification by cardiac magnetic resonance imaging without hematocrit sampling : Ready for prime time?Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.Wedge Pressure Rather Than Left Ventricular End-Diastolic Pressure Predicts Outcome in Heart Failure With Preserved Ejection Fraction.Gender-related differences in heart failure with preserved ejection fraction.Tricuspid valve replacement: results of an orphan procedure: which is the best prosthesis?Right ventricular dysfunction, but not tricuspid regurgitation, is associated with outcome late after left heart valve procedure.Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure.Prognostic Significance and Determinants of the 6-Min Walk Test in Patients With Heart Failure and Preserved Ejection Fraction.Impact of Systemic Volume Status on Cardiac Magnetic Resonance T1 Mapping.Extracellular matrix expansion by cardiac magnetic resonance T1 mapping- validation with myocardial biopsyPrevalence and prognostic significance of right ventricular systolic dysfunction in heart failure with preserved ejection fraction. Insights from a cardiac magnetic resonance imaging studyDiastolic Pressure Gradient Predicts Outcome in Patients With Heart Failure and Preserved Ejection FractionWhen it rains, it pours: Peripartum cardiomyopathy with features of left-ventricular noncompaction in a hemodialysis patientGlobal Longitudinal Strain by CMR Feature Tracking Is Associated With Outcome in HFPEFEXPRESS: Riociguat for the treatment of transthyretin cardiac amyloidosis - Data from a named patient use program in AustriaSyncope: The Underestimated Threat in Severe Aortic StenosisCardiac Magnetic Resonance T1 Mapping in Cardiac AmyloidosisMechanisms of heart failure in transthyretin vs. light chain amyloidosisWith a grain of salt: Sodium levels in heart failureDeterminants of Bioprosthetic Aortic Valve DegenerationPatients with Heart Failure and Preserved Ejection Fraction Are at Risk of Gastrointestinal BleedingAngs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection FractionWhat is normal? A central question in the application of CMR mapping techniquesNative T1 time of right ventricular insertion points by cardiac magnetic resonance: relation with invasive haemodynamics and outcome in heart failure with preserved ejection fractionDiagnostic and Prognostic Utility of Cardiac Magnetic Resonance Imaging in Aortic Regurgitation
P50
Q35061409-811141C2-03B7-40F0-B6DE-2764ABEF8F80Q35725839-67805FD5-7733-42B3-B026-B5454B10F8C4Q35751037-A8C1B313-D363-4286-A86B-5A2968DF4537Q36006309-7683EF1A-6C06-47CD-AF29-743613EDB4E4Q36281115-237AF60A-1FE4-41F8-BD5C-5CA7FC9E8DC7Q37510689-8564000E-2238-4547-9B0F-85A3D26239B8Q39035268-309BC7D7-5805-4C96-875E-482C04A250ACQ40149965-7D3F74F5-64B7-46A7-9354-1C61276197FBQ40179170-9A80DF77-D568-4D2F-8A9B-70B363CBFEBBQ40425042-BE165CC0-5065-4760-9F17-030A73F05A48Q40442223-3512F5B6-6B30-4DE1-8D34-F0D11E6F47CEQ40451398-351D9094-8750-46D5-B824-260970D8E12DQ41036082-58357405-FCAA-4988-8DF1-52535ABB9197Q41224622-504434E4-C591-4045-BF78-818FE8E8E3F4Q41577379-A6DE9EB4-C77A-4C99-9B5E-74255EDB050FQ47619369-79419D71-DF45-4BDA-9847-76FC4247584CQ47705289-DCFC4AE0-C874-443D-909F-0EA569F2F644Q47794661-F64F8710-19F9-45AE-8804-9F807C0AC0DDQ49342004-A0F98D9E-A643-4270-8EAF-3966FA48DAF8Q50070637-06E3A1F7-8734-4C17-81F9-A4DAC8BA1C49Q51068239-602B614D-BAE7-459C-991D-4789A6C93746Q52819862-C1B081D4-6E30-4160-B322-A5D1F95190B3Q53478092-661B303D-6262-447C-9D2F-DC6CF727127EQ55494001-6587B7ED-7A33-4DBE-966F-FD72E4D3066FQ59402388-2A1F774B-2E14-464C-B934-1D89CD859D62Q59425954-C6242C65-C2EC-4B68-9153-BD1DD3535C69Q86116264-18EA535E-8C0A-4FEC-AD29-84965B8CA5DDQ89373705-5D9BFC5F-C6A5-43C8-A09B-02C5EA0788ECQ90040191-6B04BE5C-B6B1-4AA3-BEFF-0A714B3FB0ABQ90087184-8BE808C1-DE25-4033-AC90-7C6F198910F3Q90554180-1708D76F-067F-4C83-B001-84C5E5102920Q91018929-287D7FB8-46D6-4AD3-97FB-7ADCC76696E2Q91071510-EA03A8B0-6285-4879-A915-DF95E00B06B5Q92323488-1E411415-6229-4D4C-9D93-173F96DC7931Q92411343-12BBA436-1D7B-426B-A925-AE06DA86DFC3Q92702829-9AD163C2-56D4-40A9-A647-27DF13D45558Q92966167-6D1BF0B5-2C1C-48B4-AC3A-FB562476BFB9Q93047859-8E9656C2-CEC0-472F-9D25-E1A93036221DQ93179990-B35E67AF-AA8A-4613-A273-18C7D6AC310EQ93192376-DD14B106-13D1-40F5-81AB-1D8982009B9B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andreas A Kammerlander
@ast
Andreas A Kammerlander
@en
Andreas A Kammerlander
@es
Andreas A Kammerlander
@nl
type
label
Andreas A Kammerlander
@ast
Andreas A Kammerlander
@en
Andreas A Kammerlander
@es
Andreas A Kammerlander
@nl
prefLabel
Andreas A Kammerlander
@ast
Andreas A Kammerlander
@en
Andreas A Kammerlander
@es
Andreas A Kammerlander
@nl
P106
P1153
55987901800
P31
P496
0000-0002-7632-9879